Celldex Therapeutics
CLDX
48 hedge funds and large institutions have $9.42M invested in Celldex Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 10 closing their positions.
133% more call options, than puts
Call options by funds: $91K | Put options by funds: $39K
7% more capital invested
Capital invested by funds: $8.8M → $9.42M (+$622K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.66% less ownership
Funds ownership: 26.42% → 23.76% (-2.7%)
11% less funds holding
Funds holding: 54 → 48 (-6)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$207K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$36.5K |
| 4 |
Morgan Stanley
New York
|
+$27.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$162K |
| 2 |
D.E. Shaw & Co
New York
|
-$36K |
| 3 |
VF
Virtu Financial
New York
|
-$30K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$23K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$21K |
CLDX Hedge Fund Activity: Q4 2019 in Review
48 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2019, worth a combined $9.42M — up 7.1% from $8.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLDX and 6 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $207K. The largest seller was Bridgeway Capital Management, cutting an estimated $162K.
- 48 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2019, down from 54 in Q3 2019.
- Funds reported $9.42M of Celldex Therapeutics stock for Q4 2019, up 7.1% quarter-over-quarter.
- 6 funds opened new Celldex Therapeutics positions in Q4 2019 and 10 closed out, a net change of -4 holders.
- The largest Celldex Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $207K added.
- The largest Celldex Therapeutics seller in Q4 2019 was Bridgeway Capital Management, an estimated $162K sold.
Based on aggregated 13F filings for Q4 2019.